Health Catalyst Inc. (HCAT)
Health Catalyst (HCAT) Upgraded to Buy: Here's What You Should Know
Health Catalyst (HCAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Health Catalyst: Still Optimistic On Achieving Adjusted EBITDA Targets
I recommend a buy rating for Health Catalyst stock. HCAT's Ignite platform is gaining traction, offering modular solutions that enhance adoption, cross-sell opportunities, and expand the total addressable market. Despite potential short-term ARPU concerns, Ignite's higher margins and ongoing migration will drive long-term profitability and significant upside by FY28.
Health Catalyst, Inc. (HCAT) Q2 2024 Earnings Call Transcript
Health Catalyst, Inc. (NASDAQ:HCAT ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Jack Knight - VP, IR Dan Burton - CEO & Director Dan LeSueur - COO Jason Alger - CFO Conference Call Participants Stephanie Davis - Barclays Anne Samuel - JPMorgan Jared Haase - William Blair Sameer Patel - Evercore ISI Richard Close - Canaccord Genuity John Ransom - Raymond James Jessica Tassan - Piper Sandler Jenny Shen - BTIG Jack Wallace - Guggenheim Securities Stan Berenshteyn - Wells Fargo Jeff Garro - Stephens Operator Welcome to the Health Catalyst Second Quarter 2024 Earnings Conference Call. At this time all participants have been placed on a listen-only mode, and the floor will be open for your questions, following the presentation.
Health Catalyst (HCAT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Health Catalyst (HCAT) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Health Catalyst (HCAT) Tops Q2 Earnings and Revenue Estimates
Health Catalyst (HCAT) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.05 per share a year ago.
3 Overlooked Telehealth Stocks Poised for a Comeback
Healthcare portfolios include telehealth stocks, notably after the COVID-19 pandemic, which increased global telemedicine usage, demonstrating their importance for lockdowns and other social isolation scenarios. The worldwide telehealth market was $122.2 billion in 2023 and is anticipated to rise 28.4% annually from 2024 to 2032.
Why Health Catalyst (HCAT) Might be Well Poised for a Surge
Health Catalyst (HCAT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts See a 75.19% Upside in Health Catalyst (HCAT): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 75.2% in Health Catalyst (HCAT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
